Hani Soudah, MD
Endocrinology, Diabetes & Metabolism · Saint Louis, MONPI 1811935471
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,657 of the $2,627 with a category attached, or 63.1%. Echosens North America, Inc. accounts for 67.3% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $2,111 and has fallen 98.3% since, to $35 in 2025.
Across 30 payments — averaging $87.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Echosens North America, Inc.$2K
- Novo Nordisk$326
- Kvk-tech, Inc.$194
- Rhythm Pharmaceuticals, Inc.$123
- Lilly USA, LLC$121
- Eisai Inc.$46
- plus $47 from 2 others
Across 15 payments — averaging $2405.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rhythm Pharmaceuticals, Inc.$36K
What the payments were for
- Consulting fees$472%
- Travel & lodging$1,65763%
- Food & beverage$87133%
- Education$522%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Echosens North America, Inc. | 3 | $1,769 |
| Novo Nordisk | 6 | $326 |
| Kvk-tech, Inc. | 14 | $194 |
| Rhythm Pharmaceuticals, Inc. | 2 | $123 |
| Lilly USA, LLC | 2 | $121 |
| Eisai Inc. | 1 | $46 |
| Boehringer Ingelheim | 1 | $35 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,627 in reported general payments places this provider in the 55th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 225 | $281,914 |
| MounjaroTirzepatide | 87 | $97,328 |
| RybelsusSemaglutide | 31 | $51,042 |
| TrulicityDulaglutide | 17 | $23,412 |
| JardianceEmpagliflozin | 15 | $21,922 |
| FarxigaDapagliflozin Propanediol | 28 | $16,807 |
| EliquisApixaban | 12 | $7,583 |
| LinzessLinaclotide | 14 | $7,329 |
| Cabergoline | 12 | $2,920 |
| Potassium Chloride | 17 | $2,429 |
| Topiramate | 191 | $2,387 |
| Naltrexone Hcl | 53 | $2,155 |
| Bupropion Hcl SrBupropion Hcl | 75 | $1,263 |
| Bupropion XlBupropion Hcl | 74 | $1,220 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 22 | $768 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $326 | $332,956256 claims |
| Lilly USA, LLCMounjaro, Trulicity | $121 | $120,740104 claims |
| Boehringer IngelheimJardiance | $35 | $21,92215 claims |
| AstraZenecaFarxiga | $12 | $16,80728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Saint Louis
- Janet McGillSaint Louis$212K
- Farid RomanSaint Louis$62K
- Kathryn DiemerSaint Louis$57K
- Julie SilversteinSaint Louis$49K
- Michael WhyteSaint Louis$40K
- Alexis McKeeSaint Louis$37K
- Sandeep DhindsaSaint Louis$36K
- Thomas NickolasSaint Louis$35K
- K ThampySaint Louis$35K
- Garry TobinSaint Louis$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.